Scarica l'app Stockscreener
0.8242
0.70%
-0.0058
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.83
Aprire:
$0.83
Volume 24 ore:
589.55K
Relative Volume:
0.88
Capitalizzazione di mercato:
$114.38M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-3.7464
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
-0.22%
1M Prestazione:
+6.06%
6M Prestazione:
-12.70%
1 anno Prestazione:
-31.32%
Intervallo 1D:
$0.8201
$0.8465
Intervallo di 1 settimana:
$0.805
$0.92
Portata 52W:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Confronta ATOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8242 | 114.38M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com
Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq
Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada
Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus
Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener
Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus
Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria
Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire
Atossa Therapeutics announces issuance of U.S. patent - MSN
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus
Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan
HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Phase 2 Trial: New Breast Cancer Drug Achieves 77.7% Tumor Shrinkage with Minimal Side Effects - Stock Titan
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atossa Therapeutics Inc Azioni (ATOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):